Abstract

This research aims to comprehensively evaluate the safety and efficacy of anlotinib, and quantify its treatment effect in advanced metastatic colorectal cancer patients. 150 advanced metastatic colorectal cancer patients received third-line or more treatment in the oncology department of a tertiary hospital from January 2019 till January 2022. Their clinical data were collected and retrospectively analyzed. We evaluated the efficacy and adverse reactions of anlotinib. The objective remission rate of patients was 10 %, while the disease control rate was 64 %. The median progression-free survival time was 4.1 mo. It is revealed that liver metastasis and eastern cooperative oncology group score were related to progressionfree survival by univariate analysis. It is showed by multivariate analysis that liver metastasis was an independent factor that influencing the treatment of advanced metastatic colorectal cancer (p<0.05). Hypertension, fatigue, nausea and vomiting, albuminuria, and hypothyroidism were the relatively high incidences of complications caused by anlotinib. Anlotinib as the third line and above treatment is both effective and safe in treating advanced metastatic colorectal cancer.